In the last decade, the field of mRNA has made significant progress and has emerged as a highly attractive means of encoding and producing any protein of interest in vivo. Equipped with state-of-the-art facilities and experienced immunology experts, Creative Biolabs has expanded its service capabilities to offer mRNA encoded antibody products for global clients to best suit your program requirements.

mRNA based antibodies as a new appealing therapeutic solution

As a transient carrier of information, exogenous mRNA is considered to be a powerful tool to guide a body to produce its own therapeutics. Based on the structural elements of the mRNA, which have an impact on its performance, including potential immunogenicity, efficacy of translation and stability of the molecule. Nowadays, several studies have showed that antibody-encoding, sequence-optimized or unmodified mRNA in LNPs empowered mice model to successfully fight a variety of biological threats, such as toxins, viruses, and tumors, which indicates that mRNA encoded antibodies will have great potential in therapeutic fields, such as cancer, infectious diseases areas.

Compared to traditionally expressed antibodies, production and purification of mRNA encoded antibodies has a lot of advantages.

Our mRNA technologies

Based on the mRNA technologies, Creative Biolabs will leverages our extensive experience to design and synthesize our mRNA encoded antibodies, and optimize its composition to suit the desired application.

Creative Biolabs is dedicated to helping our worldwide customers shorten the discovery and development time in mRNA encoded antibodies. We utilize unrivaled, proprietary structure design, study data, product candidate, advanced project life-cycle management, as well as real-time data to ensure the ideal outcomes.

For more detailed information, please feel free to contact us or directly send us an inquiry.

References

1. Schlake T, Thran M, Fiedler K, et al. mRNA: a novel avenue to antibody therapy?. Molecular Therapy. 2019 Apr 10;27(4):773-84.
2. Mu Z, Haynes BF, Cain DW. HIV mRNA Vaccines—Progress and Future Paths. Vaccines. 2021 Feb;9(2):134.
3. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nature reviews Drug discovery. 2014 Oct;13(10):759-80.
4. Van Hoecke L, Roose K. How mRNA therapeutics are entering the monoclonal antibody field. Journal of translational medicine. 2019 Dec;17(1):1-4.

Hot Products:

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.